Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.

Notably, the APBC treatment resulted in extremely significant increase in the percentage of IFN-γ and TNF-α producing CD4 + T cells within the spleens of mice when compared with vehicle control ( Fig. 7 A and B).

also in 7,787 other papers